Abstract
Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have